コンテンツへスキップ
Merck
  • Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Brain & development (2010-07-16)
Vincenzo Belcastro, Laura Pierguidi, Nicola Tambasco
要旨

Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection. Recent observations suggest that levetiracetam is both safe and effective against post-stroke seizures. In this review, the potential neuroprotective role in brain ischemia and the therapeutic implications of levetiracetam in post-stroke epilepsy are discussed.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
レベチラセタム, ≥98% (HPLC)
Supelco
レベチラセタム, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
レベチラセタム 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
レベチラセタム, United States Pharmacopeia (USP) Reference Standard
レベチラセタム, European Pharmacopoeia (EP) Reference Standard